-
IRhythm Technologies Is Breaking Ground In Cardiac Monitoring, Says New Sell-Side Bull
Tuesday, March 6, 2018 - 1:43pmMedtech name IRhythm Technologies Inc (NASDAQ: IRTC) is redefining how cardiac arrhythmias are monitored, which makes the stock an attractive buy, according to BMO Capital Markets. The Analyst BMO analyst Joanne Wuensch initiated coverage of iRhythm Technologies' stock with an...
Read More >> -
Analyst: Insulet On Track For Profitability In 2018
Tuesday, March 6, 2018 - 12:51pmInsulet Corporation (NASDAQ: PODD) is up 80.5 percent year-over-year, and even last quarter’s bottom-line miss can’t deter the biotech’s bulls. The Rating BMO Capital Markets analyst Joanne Wuensch initiated coverage of Insulet Corp. with an Outperform rating and $90 price...
Read More >> -
Becton Dickinson Has A Strong, Diverse Pipeline, But Is Fairly Valued, Says BMO
Tuesday, March 6, 2018 - 12:37pmWith a presence across 10 markets, leadership in some segments and a "robust" product pipeline, Becton Dickinson and Co (NYSE: BDX) is "more than just needles and syringes," according to BMO Capital Markets. The Analyst BMO analyst Joanne Wuensch initiated coverage...
Read More >> -
After Recent Run, Penumbra Downgraded On Fears Its Upside Is Exhausted
Tuesday, December 12, 2017 - 4:10pmThe medical device company Penumbra Inc (NYSE: PEN) issued a consensus-beating earnings report Nov. 7. The Analyst BMO Capital Markets' Joanne Wuensch downgraded Penumbra from Outperform to Market Perform and reduced the price target from $117 to $110. The Thesis The analyst said...
Read More >> -
Abbott Laboratories Makes BMO Capital's Top Picks List
Tuesday, December 12, 2017 - 1:34pmAbbott Laboratories (NYSE: ABT) had a busy 2017 after acquiring Alere and St. Jude Medical, earning the stock a nod of approval from a Wall Street analyst. The Analyst BMO Capital Markets' Joanne Wuensch upgraded Abbott's stock rating from Market Perform to Outperform with a price target...
Read More >> -
BMO On Abbott Labs: 'It's Likely Time For The Stock To Take A Pause'
Tuesday, March 14, 2017 - 12:08pmBMO downgrades Abbott Laboratories (NYSE: ABT) to Market Perform from Outperform as shares are trading near the brokerage’s $48 price target. Abbott shares have outperformed year-to-date, increasing 19 percent versus the S&P 500’s 6 percent. BMO views some of this as a “...
Read More >> -
Endologix Sees FDA Approval Of Nellix Remaining Elusive; BMO Downgrades
Thursday, November 17, 2016 - 12:40pmBMO Capital Markets has downgraded Endologix, Inc. (NASDAQ: ELGX) to Market Perform from Outperform after FDA’s request of two-year follow-up data from Nellix clinical study, instead of a one-year follow-up. The news sent the company's shares in to a tailspin. The Nellix Issue The Nellix...
Read More >> -
Potential 21% Upside Seen For Shares Of Recent IPO Penumbra
Monday, October 17, 2016 - 1:16pmBMO Capital Markets started coverage of Penumbra Inc (NYSE: PEN) with an Outperform rating and price target of $86, implying potential upside of 21 percent. Although it's a recent IPO, the brokerage pointed out that the company’s 2015 revenue rose 53 percent to $186 million, including...
Read More >> -
Cooper Companies Third Quarter Good, Not Great, Says BMO
Friday, September 2, 2016 - 11:25amCooper Companies Inc (NYSE: COO) reported its third-quarter results after Thursday's market close. The company said it earned $2.30 per share in the quarter on revenue of $514.7 million, exceeding the $2.29 per share and $511.8 million Wall Street analysts were expecting. According to Joanne...
Read More >> -
Expect Conservative Guidance For Medical Tech Stocks?
Friday, January 22, 2016 - 12:11pmOn Thursday, BMO Capital Markets issued a report on the Medical Technology industry ahead of the fourth quarter earnings season. Analysts highlighted multiple companies including Abbott Laboratories (NYSE: ABT), Wright Medical Group Inc. (NASDAQ: WMGI), and Stryker Corporation (NYSE: SYK). Joanne...
Read More >>